MacroGenics, Inc. , a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
Macrogenics stock last closed at $16.07, down 0.19% from the previous day, and has increased 138.07% in one year. It has overperformed other stocks in the Biotechnology industry by 1.65 percentage points. Macrogenics stock is currently +274.59% from its 52-week low of $4.29, and -26.55% from its 52-week high of $21.88.
As of Apr 18, 2024, there are 62.43M shares of MGNX outstanding. The market cap of MGNX is $1.00B. In the last 24 hours, 585,939 MGNX shares were traded.
How to Buy Macrogenics Stock
Wondering how to invest in Macrogenics stock? Here's how.
Figure out where to buy Macrogenics stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you figure out where to buy Macrogenics stock.
Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Put funds into your investment account: Choose your payment method and add your details.
Evaluate Macrogenics stock: The Macrogenics ticker symbol is MGNX. Is Macrogenics stock a good investment? Should you buy shares of MGNX? How do MGNX's underlying business fundamentals look? Do top analysts think Macrogenics is a good buy? Why has MGNX's stock price moved recently? (Hint: Our stock market research tools can help you figure out if MGNX is a good stock to buy).
Execute your MGNX trade: Decide if you will purchase MGNX shares at the current market price or use a limit order to buy MGNX shares at a specific price.
Keep an eye on your MGNX investment: Create a watchlist to monitor your new investment in Macrogenics stock.
Step 1: Figure out where to buy Macrogenics stock
You will need a brokerage account in order to access the NASDAQ market and buy MGNX shares.
A brokerage account allows you to buy and sell a number of investments, including stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to global financial markets: From Tech to Utilities, New York to Hong Kong — you can fill your portfolio with stocks from the world's top stock exchanges.
Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro now.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create your brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal info so you can buy MGNX today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Macrogenics stock
After you have selected the best place to buy Macrogenics stock, it's very important to research their stock prior to investing, so you truly comprehend the risk as well as the opportunity.
Overview of key MGNX info
MGNX Price
$16.07
1w %
-13.18%
1y %
138.07%
5y %
-0.86%
P/E
-107.13x
P/B
6.57x
P/S
16.93x
PEG
N/A
Revenue
$58.75M
Earnings
-$9.06M
Fore. Rev. Growth
55.32%
Fore. Earn. Growth
N/A
Market Cap
$1.00B
Next Earnings
May 7, 2024
Next Dividend
N/A
MGNX Overview
WallStreetZen was designed to help everyday investors perform more accurate fundamental analysis.
MGNX has cash burn of 79905000. It has sufficient cash and short-term investments to cover this for at least one year.
MGNX profit margin has gone up from -78.8% to -15.4% in the past year.
MGNX has $229.81M in cash and short term investments. This is enough to cover its annual cash burn of $79.91M.
There are more short-term assets than short-term liabilities on the MGNX balance sheet.
There are more short-term assets than long-term liabilities on the MGNX balance sheet.
Negative Health Checks:
MGNX has a relatively high debt to equity ratio of 0.96.
Total MGNX debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy Macrogenics stock
Out of 9 Equities analysts who research MGNX, the consensus analyst rating on Macrogenics is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent MGNX Analyst Upgrades/Downgrades
Peter Lawson, a top 22% analyst from Barclays maintains MGNX with a strong buy rating and raises their MGNX price target from $23.00 to $25.00, on Mar 8, 2024.
Barclays's Peter Lawson raised their price target on Macrogenics (NASDAQ: MGNX) by 8.7% from $23 to $25 on 2024/03/08. The analyst maintained their Strong Buy rating on the stock.
Lawson's price target increase followed a review of Macrogenics Q4 and FY 2023 earnings, reported on 2024/03/07.
The company's cash runway was reiterated into 2026, the analyst told readers.
Kaveri Pohlman, a bottom 12% analyst from BTIG maintains MGNX with a strong buy rating and raises their MGNX price target from $12.00 to $24.00, on Mar 4, 2024.
Jonathan Block, a bottom 21% analyst from Stifel Nicolaus reiterates MGNX with a strong buy rating and maintains their MGNX price target from $17.00 to $17.00, on Nov 27, 2023.
Charles Zhu, a top 19% analyst from Guggenheim upgrades MGNX to a strong buy rating and announces their MGNX price target of $12.00, on Nov 7, 2023.
Last year, MGNX revenue was $58.75M. In the last 5 year, MGNX's revenue has gone up by -0.46% per year. This was slower than the Biotechnology industry average of 28.98%.
Over the past 12 months, executives and large shareholders at MGNX have bought more shares than they have sold.
Jeffrey Stuart Peters, Senior VP and General Counsel of MGNX, was the latest MGNX insider to sell. They sold $57,666.30 worth of MGNX stock on Apr 4, 2024.
No, Macrogenics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your MGNX trade
There are two main order types:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are usually fine for most investors.
Limit order: A limit order enables you to buy or sell a security at a specific price (or better). If you want to be sure you're buying or selling at a particular dollar amount limit, place a limit order.
Click the Open button and your broker will place the order.
If you need additional help with buying stocks on eToro, click the helpful video below:
How much does it cost to buy one Macrogenics share?
As of Apr 18, 2024, it costs $16.07 to buy one share of Macrogenics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $8, you can buy 0.498 shares of MGNX.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.